Health Care Equipment

Alpha Tau Medical

Alpha Tau Medical released FY2026 Q1 earnings on May 18 (EST), actual revenue USD 0 (forecast USD 66.33 K), actual EPS USD -0.26

Alpha Tau Medical REGAIN Trial Shows Positive Results for Glioblastoma Treatment

Alpha Tau Medical Ltd. Completes Patient Recruitment for Alpha DaRT Radiotherapy Key Clinical Trial

Alpha Tau Medical released FY2025 earnings on March 9, 2026 (EST), with actual revenue of USD 0 and EPS of USD -0.5289

Alpha Tau Medical released FY2025 Q4 earnings on March 9, 2026 (EST), with actual revenue of USD 0 and EPS of USD -0.1417

Alpha Tau Medical released FY2025 9 Months earnings on November 20 (EST), actual revenue USD 0, actual EPS USD -0.3861

Alpha Tau Medical released FY2025 Q3 earnings on November 20, 2025 (EST), with actual revenue of USD 0 and EPS of USD -0.137

Alpha Tau Medical released FY2025 Q2 earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1264 (forecast USD --)

Alpha Tau Medical released FY2025 Semi-Annual earnings on August 11 (EST), actual revenue USD 0, actual EPS USD -0.2492

Alpha Tau Medical Sees Share Price Rise and Maintains Buy Rating

Alpha Tau Medical Ltd. to Speak at Jefferies Global Healthcare Conference

Alpha Tau Medical released FY2025 Q1 earnings on May 19 (EST), actual revenue USD 0 (forecast USD 25K), actual EPS USD -0.1233

Alpha Tau Medical Ltd. urges shareholders to vote in favor of all proposals

Alpha Tau Medical Ltd. Receives FDA Approval for Investigational Device Exemption for Cancer Treatment

Alpha Tau Medical released FY2024 annual earnings on March 12 (EST), actual revenue 0 USD, actual EPS -0.454 USD

Alpha Tau Medical released FY2024 Q4 earnings on March 12 (EST), actual revenue 0 USD, actual EPS -0.1351 USD

Alpha Tau Medical Ltd. FDA Approves Expansion of Alpha DaRT Trial to 30 Pancreatic Cancer Patients

Promising Results of Alpha DaRT® Efficacy Trials in Pancreatic Cancer Patients

Alpha Tau Medical released FY2024 Q3 earnings on November 19 (EST) with actual revenue of 0 USD and EPS of -0.0989 USD

Alpha Tau Medical released FY2024 Cumulative 3Q Earnings on November 19 (EST), Revenue: 0, EPS: -0.3188

Micware

Silexion Therapeutics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Linkage Global

GCL Global

Jupiter Neurosciences

Capstone

Arcadia Biosciences

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Earning Release

业绩披露

2026.05.18 (EST) Announced FY2026 Q1 Earning Release (USD) Revenue 0, Net Income -22.94 M, EPS -0.26

DRTS

Alpha Tau Medical Ltd. reported a Q1 2026 net loss of $22.9 million, up from $8.7 million a year prior. The company plans to complete patient recruitment for its IMPACT pancreatic cancer study by Q3 2026 and expects initial data by late 2026. The stock closed at $10.03, down 3.19%, but rose 3.09% in pre-market trading to $10.34.

nasdaq

Nasdaq

ALPHA TAU MEDICAL LTD C/WTS (TO PUR COM)

Alpha Tau Q1 Net Loss Expands; Plans Enrollment Completion In IMPACT Study In Q3,2026; Stock Up

ARKG

Dror Ortho-Design, Inc. reported a net loss of $(638,666) for Q1 2026, with diluted EPS of $(0.00). The company remains in the development stage with no material revenue. R&D spending decreased by 51% year-over-year. The company is preparing a new 510(k) submission for FDA clearance and aims to disrupt the aligner market with a smart aligner platform. Operations depend on raising additional capital for regulatory work and development. Following a share exchange in 2023, the company integrated a new management team for commercialization efforts.

TradingView

Ark Genomic Revolution ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

VG Health

iShares Global Healthcare

iShares US Pharma

Direxion S&P Biotech Bear 3X

Dror Ortho-Design, Inc. 1Q 2026: Net income $(638,666), EPS $(0.00) — 10-Q Summary

HRTX

CNSP

CODX

In Monday's trading session, several health care stocks experienced significant movements. Pomdoctor (POM) surged 185.9% to $0.21, while Intelligent Bio Solutions (INBS) rose 35.59% to $3.2. Other gainers included Odysight ai (ODYS) up 26.0% to $5.62, Exagen (XGN) up 24.74% to $3.68, and Alpha Tau Medical (DRTS) up 22.32% to $10.41. Conversely, WORK Medical Tech Gr (WOK) fell 33.3% to $0.85, Co-Diagnostics (CODX) dropped 23.72% to $1.93, and Heron Therapeutics (HRTX) decreased 22.04% to $0.94. Bristol-Myers Squibb (CELGR) shares fell 18.32% to $0.11, while Certara (CERT) declined 18.15% to $5.17. CNS Pharmaceuticals (CNSP) also saw a drop of 17.29% to $6.03.

benzinga_article

Heron Therap

Bristol Myers Squibb

CNS Pharma

Exagen

Pomdoctor

Co-Diagnostics

Intelligent Bio Solutions

Odysight.ai

Lexicon Pharma

WORK Medical Tech

Bristol-Myers Squibb Company

Certara

12 Health Care Stocks Moving In Monday's Intraday Session

Alpha Tau Medical (NASDAQ:DRTS) shares hit a new 52-week high of $9.90, closing at $9.9750 with a trading volume of 1,997,160 shares. Analysts have mixed ratings: Piper Sandler maintains a "neutral" rating with a $5.00 target, while HC Wainwright has a "buy" rating with a $12.00 target. The stock has a market cap of $897.35 million and a P/E ratio of -19.28. The company focuses on targeted alpha-radiation therapies for solid tumors, with its lead product, Alpha DaRT, in clinical studies for various cancers.

Market Beat

Piper Sandler Cos

Alliance HC

REPUBLIC HC

Hancock Whitney

Nano Labs

Citigroup

Weis Markets

Carl Zeiss Meditec AG

NEUBERGER BERMAN REAL ES-W/I

Zacks Quality International ETF

Zacks Focus Growth ETF

Zacks Small/Mid Cap ETF

Gulf Marine Services PLC

Vision Marine Tech

RanMarine Technology B.V.

Logan Capital Broad Inno Growth ETF

Trinity Capital

Brown Advisory US Smaller Companies PLC GBP

Levi Strauss

Atom Livin Tech Co., Ltd.

Sun Capital Management Corp.

Eneti

Enovix

Investar

Wells Fargo

Mercadolibre

GS MarketBeta US Equity ETF

GS MarketBeta Intl Equity ETF

MarketWise

Hancock Whitney Pref Share HWCPZ 6.25 06/15/60

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Trinity Capital Pref Share TRINL 7 01/16/25

TRINITY CAPITAL INC 7.875% NTS 30/09/2029

TRINITY CAPITAL INC 7.875% NOTES DUE 2029

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Alpha Tau Medical (NASDAQ:DRTS) Sets New 52-Week High  - Time to Buy?

Alpha Tau Medical Ltd presented interim data from its U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma on May 11, 2026. The update indicates incremental clinical progress but does not commit to specific regulatory outcomes. The company is also pursuing studies in other cancers, aiming for U.S. regulatory submissions. Analysts rate DRTS stock as a Buy with a $12.00 price target, though concerns about financial performance and funding risks persist. Alpha Tau focuses on localized cancer treatment using its radiotherapy platform targeting hard-to-treat tumors.

Tip Ranks

Alpha Tau Medical Shares Interim U.S. Glioblastoma Trial Data for Alpha DaRT

Shares of Alpha Tau Medical Ltd. (DRTS) rose over 12% to $9.60 in premarket trading following positive interim results from its REGAIN trial for recurrent glioblastoma. The study, which aims to assess the safety and feasibility of Alpha DaRT treatment, showed that two out of three patients had a complete response, with no visible tumor lesions. Chief Medical Officer Robert Den expressed optimism about the results, highlighting the potential for advancing the trial.

rttnews

Alpha Tau REGAINs Momentum On Brain Cancer Study Data

ZYBT

APUS

LGVN

In Monday's pre-market session, several health care stocks saw significant movement. Alpha Tau Medical (DRTS) rose 13.5% to $9.66, while Zhengye Biotechnology (ZYBT) increased by 12.69% to $1.07. Valneva (VALN) shares climbed 11.98% to $6.26, and Exagen (XGN) rose 11.88% to $3.3. Conversely, First Tracks (TRAX) fell 13.2% to $16.97, and Aditxt (ADTX) dropped 12.88% to $0.1. Other notable losers included Apimeds Pharmaceuticals (APUS) and Longeveron (LGVN), which saw declines of 10.7% and 8.9%, respectively.

Alpha Tau Medical(DRTS.US)

Alpha Tau Q1 Net Loss Expands; Plans Enrollment Completion In IMPACT Study In Q3,2026; Stock Up

Dror Ortho-Design, Inc. 1Q 2026: Net income $(638,666), EPS $(0.00) — 10-Q Summary

12 Health Care Stocks Moving In Monday's Intraday Session

Alpha Tau Medical (NASDAQ:DRTS) Sets New 52-Week High - Time to Buy?

Alpha Tau Medical Shares Interim U.S. Glioblastoma Trial Data for Alpha DaRT

Alpha Tau REGAINs Momentum On Brain Cancer Study Data

12 Health Care Stocks Moving In Monday's Pre-Market Session

Trending